相关实验视频

Updated: Jan 14, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

在AML中可测量的残留疾病干预:一个新的治疗视野

Andrew H Wei^1,2, Harry J Iland³, Courtney D DiNardo⁴

¹Department of Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia.

|October 17, 2025

概括

可测量的残留疾病 (MRD) 监测对于急性髓性白血病 (AML) 复发预测至关重要. INTERCEPT试验平台旨在为AML患者个性化预防性MRD导向疗法,改善治疗结果.

科学领域:

血液学血液学血液学
在瘤学瘤学.
临床试验临床试验

背景情况:

急性髓性白血病 (AML) 的特点是缓解后复发率高.
可测量的残留疾病 (MRD) 是一个预后指标,有越来越多的证据表明预防性,针对MRD的治疗.
目前的反洗钱监测缺乏通用MRD标记,需要个性化的方法.

研究的目的:

开发一种新的多目标,多臂平台试验 (INTERCEPT),用于AML的MRD导向治疗.
为了应对多个MRD标记物和疗法的后勤挑战.
为了使MRD标记物的自适应扩展和有针对性的治疗.

主要方法:

开发具有适应性特征的INTERCEPT平台试验.
实施一个集中的MRD监控框架.
使用临床决策规则方法来对治疗分配进行等级化.
创建行业合作伙伴整合的并行协议附件.

主要成果:

INTERCEPT试验旨在尽量减少MRD复发到治疗开始的时间.
它有助于无过渡到集中的MRD监控.
该平台支持多个行业合作伙伴和适应性治疗扩展.

结论:

该INTERCEPT试验代表了针对AML的MRD导向治疗的创新方法.
成功取决于快速诊断,协调后勤和适应性临床试验设计.
该平台旨在通过基于MRD水平的个性化治疗来改善AML患者的治疗结果.

更多相关视频

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...